PI
ZYNE

Putnam Investments’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Putnam Investments’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,970
Closed -$562K – 1333
2017
Q1 		$562K Sell
27,970
-18,534
-40% -$368K ﹤0.01% 1091
2016
Q4 		$725K Buy
+46,504
New +$626K ﹤0.01% 1068

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Putnam Investments's ZYNE Position: Q2 2017 in Review

Putnam Investments sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2017, closing a stake of 27,970 shares — an estimated $562K sold.

Putnam Investments first reported a position in ZYNE in Q4 2016 and held it in 2 quarters. The position peaked at $725K in Q4 2016. 66 funds tracked by Wall St. Rank hold ZYNE as of Q2 2017.

  • Putnam Investments reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Putnam Investments sold 27,970 Zynerba Pharmaceuticals, Inc shares in Q2 2017, an estimated $562K.
  • Putnam Investments first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and held it in 2 quarters.
  • Putnam Investments's Zynerba Pharmaceuticals, Inc position peaked at $725K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2017.

Based on Putnam Investments's 13F filing for Q2 2017, filed 14 Aug 2017.